Amgen Inc.

Jinqian Liu

Rajiv Sharma

Julio Cesar Medina

Jonathan B Houze

Zhihua Ma

Jiwen Liu

Yingcai Wang

Michael J Schmitt

XianYun Jiao

Stephen J Shuttleworth

Frank Kayser

Wang Shen

Liusheng Zhu

Zice Fu

Paul John Dransfield

Michelle Akerman

Wei Qiu

David Craig McGowan

Jian Luo

Sean P Brown

Hilary Plake Beck

Christopher Neil Farthing

Sarah Lively

Zhongyu Wang

Todd J Kohn

Marc Vimolratana

Jian Zhang

SuJen Lai

Daniel C H Lin

Alexander David Frenkel

Jeffrey D Reagan

Ying Sun

Martin J Harrison

Matthew W Martin

Jean E Bemis

Xiaohui Du

Ryan D White

Xiaotian Zhu

David John Kopecky

Ming Yu

Leping Li

Vatee Pattaropong

Joseph J Nunes

Erin F DiMauro

John Laird Buchanan

Mike Elias Lizarzaburu

Jiasheng Fu

Yong-Jae Kim

William H Buckner

Teresa L Marshall

Simon A Burkitt

Simon Turcotte

Paul Faulder

Provided herein are compounds of formula I: wherein A, B, X, R, Rand subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions. 

Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Heterocyclic GPR40 modulators

The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formulaQ-L-P-L-M-X-L-Awherein the definitions of the variables Q, L, P, L, M, X, Land A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.

Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders

The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I. The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula I.

Furanopyrimidines

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Benzo-fused compounds for use in treating metabolic disorders

The present invention relates to furanopyridine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of modulating Lck and ACK-1 enzymes and of treating various related diseases and conditions, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, comprising administering to the mammal a therapeutically effective amount a compound of Formula I, as described above, and methods of manufacturing medicaments comprising the compound of Formula I.

Furanopyridine derivatives and methods of use

The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formulaQ&#x2014;L&#x2014;P&#x2014;L&#x2014;M&#x2014;X&#x2014;L&#x2014;Awherein the definitions of the variables Q, L, P, L, M, X, Land A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L, L, M, X, L, and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders

Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided herein.

Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity

Growing community of inventors

Palo Alto, CA, United States of America

Jinqian Liu